Hanover, United States
Autem Therapeutics, operating under the slogan "EM-Powering Cancer Care," is a pioneering company in the Biotechnology and Health Care sectors. Based in Hanover, NH, USA, and founded in 2017, this privately held firm is at the forefront of developing a novel, non-invasive treatment platform targeting solid tumors like hepatocellular carcinoma (HCC) and glioblastoma (GBM).
Their innovative device, the AutEMsys, uses personalized, amplitude-modulated electromagnetic frequencies (AM-EMF) and has already achieved FDA breakthrough designation for advanced HCC. Early clinical feasibility studies indicate potential in tumor size reduction and improved patient outcomes. The company eyes FDA Investigational Device Exemptions (IDE) for HCC and GBM trials by late 2025.
After securing a $10.00M Series A investment from Zentynel Frontier Investments in June 2022, Autem Therapeutics is strategically positioned for upcoming clinical trials and regulatory milestones, offering promising opportunities for investors.
